Investigational drug study for Hepatocellular Carcinoma

Trial ID:
IRB-19-7369
Catherine Frenette, MD
This study is looking at treating patients with advanced liver cancer using an immunotherapy drug called atezolizumab, in combination with a chemotherapy drug called cabozantinib. Atezolizumab works to stimulate the immune system to destroy cancer cells. Cabozantinib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Study subjects will be assigned by chance to receive one of 3 treatments: a combination of cabozantinib and atezolizumab, only cabozantinib or only sorafenib, which is the current chemotherapy treatment for liver cancer.

Inclusion Criteria

  • Be 18 years of age or older
  • Have been diagnosed with hepatocellular carcinoma
  • Not be eligible for curative treatment such as a transplant, surgery or ablation therapy or localized therapy such as TACE

Exclusion Criteria

  • Have received prior systemic therapy such as chemotherapy, small molecule kinase inhibitors and immune checkpoint inhibitors
  • Have been diagnosed with fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma
  • Have been diagnosed with hepatic encephalopathy or require medication for prevention or control of encephalopathy within 6 months
  • Have clinically meaningful ascites (ascites requiring treatment) within 6 months

Additional Info

  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines.

Contact Info: